Core Insights - Natera reported a revenue of $592.18 million for the quarter ended September 2025, reflecting a year-over-year increase of 34.7% [1] - The company's EPS was -$0.64, a decline from -$0.26 in the same quarter last year, indicating a significant drop in profitability [1] - Revenue exceeded the Zacks Consensus Estimate of $511.52 million by 15.77%, while the EPS fell short of the consensus estimate of -$0.39 by 64.1% [1] Financial Performance - The processed volume of tests reached 893,600, surpassing the average estimate of 860,882 from three analysts [4] - Product revenues amounted to $590.2 million, exceeding the four-analyst average estimate of $504.42 million, marking a year-over-year increase of 35.3% [4] - Licensing and other revenues were reported at $1.99 million, below the average estimate of $3.19 million, representing a year-over-year decline of 45.3% [4] Stock Performance - Natera's shares have increased by 16.2% over the past month, significantly outperforming the Zacks S&P 500 composite, which saw a change of 1.3% [3] - The stock currently holds a Zacks Rank 4 (Sell), suggesting potential underperformance relative to the broader market in the near term [3]